Metabolic effects of cabergoline in prolactinoma patients
Treatments studied
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study looks at metabolic health (like blood sugar and cholesterol) in people with prolactinomas who are being treated with the drug cabergoline. It aims to understand how lowering prolactin affects the body's metabolism and may help guide better care for patients with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with a prolactinoma (a type of pituitary tumor causing high prolactin levels).
- Your prolactin levels were at least two times the normal upper limit when diagnosed (confirmed by imaging).
- You are currently taking cabergoline and your prolactin levels have returned to normal.
- You do not have any of the following: recent substance abuse, psychotic disorder, severe liver/kidney disease, fibrotic disorders, or recent pregnancy/breastfeeding.
- You are not taking certain other medicines (strong CYP3A4 inhibitors) and have not had stomach/intestine surgery that affects absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This study looks at how changes in estrogen before diagnosis affect the growth of prolactin-secreting pituitary tumors (prolactinomas). The goal is to understand why some tumors are larger than others.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This trial tests if cabergoline can help reduce high prolactin levels caused by antipsychotic medications in people with schizophrenia. It may be an option if you have symptoms like breast tenderness, milk production, or sexual side effects.
This trial compares two medications, cabergoline and bromocriptine, to see which works better for women with high prolactin levels (hyperprolactinemia). It aims to find a more effective treatment to help manage this condition, which can affect fertility and menstrual cycles.
This trial tests if cabergoline, a medicine, can help shrink nonfunctioning pituitary adenomas (benign tumors on the pituitary gland that don't produce excess hormones). It may be an option for people who have not had prior radiation or surgery, and whose tumors are at least 0.5 cm in size.
Hear when a new Prolactinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.